A PHASE IIIB, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY AND EFF

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究将比较HIV-1感染的两种治疗方法，治疗的目标是将病毒载量降低到无法检测的水平。此外，还将评估GW433908/利托那韦与洛匹那韦/利托那韦（Kaletra）的安全性和有效性。大约866名受试者将被纳入这项多中心研究，预计有10名受试者参与该研究。研究参与将持续约52周，将需要12次研究访问。研究程序包括病史、体格检查、hiv相关状况评估、血液检查、药代动力学分析和可选的药物遗传学测试

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will compare two treatments for HIV-1 infection with the goal of therapy being to decrease the viral load to undetectable levels. In addition, the safety and efficacy of GW433908/ritonavir versus lopinavir/ritonavir (Kaletra) will be assessed. Approximately 866 subjects will be enrolled in this multi-center study with an expected participation of 10 subjects at this site. Study participation will last approximately 52 weeks and will require 12 study visits. Study procedures include medical histories, physical exams, HIV-associated condition assessments, blood tests, pharmacokinetic analysis, and optional pharmacogenetic testing